Ligand Pharma (LGND) Tops Q3 EPS by 50c ; Offers Guidance

Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $1.84, $0.50 better than the analyst estimate of $1.34. Revenue for the quarter came in at $51.81 million versus the consensus estimate of $40.6 million.

GUIDANCE:

Ligand Pharma sees FY2024 EPS of $5.50-$5.70, versus the consensus of $5.39. Ligand Pharma sees FY2024 revenue of $160-165 million, versus the consensus of $156.3 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• TD Cowen Upgrades Targa Resources (TRGP) to Buy, 'Wet Gas Fuels Growth'
• Inhibrx Biosciences (INBX) Reiterated at Market Perform by Citizens on INBRX-106 Ph2 Results
• TORM raises share capital via RSU exercise under incentive program